Small Molecule Drug Development for Bladder Cancer
Compared to conventional therapies, targeted therapy offers advantages in terms of selectivity, efficacy, and tolerability. Small molecule drugs represent a key component of the primary targeted therapies employed for cancer treatment. Alfa Cytology specializes in the development of customized small molecule drugs specifically tailored for bladder cancer.
Introduction to Small Molecule Drug
Bladder cancer is a prevalent malignancy requiring a comprehensive treatment strategy involving surgery, radiation therapy, and chemotherapy. Small molecule drugs are crucial in bladder cancer treatment as they specifically act on molecular targets within tumor cells to inhibit tumor growth, spread, and survival for therapeutic benefits. A key advantage of small-molecule drugs lies in their compact molecular structure which enables easy passage through cell membranes to interact with targets within tumor cells.
Fig.1 Neoadjuvant cisplatin-based chemotherapy in patients with bladder cancer. (Stecca C., et al. 2021)
Commonly used small molecule drugs in bladder cancer treatment include the following.
| Small Molecule Drug |
Mechanism |
| Gemcitabine |
Gemcitabine is an antimetabolic agent that induces apoptosis in tumor cells by inhibiting DNA synthesis. It is commonly administered in combination with cisplatin (a platinum-based drug) for the treatment of advanced bladder cancer. |
| Cisplatin |
The compound cisplatin functions as a DNA cross-linking agent, inducing tumor cell death through its binding to DNA and subsequent formation of DNA adducts. As a widely utilized platinum-based chemotherapeutic drug, it plays a pivotal role in the treatment of bladder cancer. |
| Vinflunine |
Vinflunine is a potent inhibitor of microtubule polymerization, effectively arresting tumor cell mitosis by suppressing microtubule dynamics and inducing cellular apoptosis. This compound has gained regulatory approval for the treatment of metastatic bladder cancer. |
| Erlotinib |
The drug Erlotinib functions as an inhibitor of the epidermal growth factor receptor (EGFR), effectively impeding the proliferation and metastasis of malignant cells through its suppression of the EGFR signaling pathway. |
| Pazopanib |
The multi-target tyrosine kinase inhibitor pazopanib predominantly suppresses the activity of VEGFR, PDGFR, and FGFR receptors, thereby effectively inhibiting tumor angiogenesis and proliferation. |
Our Services
As a leading preclinical contract research organization (CRO) specializing in bladder cancer, we are fully committed to delivering exceptional small molecule drug development services to our esteemed clients. Alfa Cytology's dedicated team possesses extensive experience and expertise necessary to provide comprehensive support for your bladder cancer drug discovery program.
| Utilizing advanced techniques and computational methods to design efficient therapeutic drugs for bladder cancer. |
Quickly assessing and screening compounds with potential therapeutic effects using high-throughput screening technology. |
| Optimizing hit compounds to create lead compounds with improved efficacy. |
Further refining and improving lead compounds to enhance their efficacy and pharmacokinetic properties. |
Workflow of Small Molecule Drug Development
| SAR/SPR Analysis |
Design |
Synthesis |
|
|
 |
|
In-Vitro Characterization |
ADME/T |
PK |
|
Contact Us
Regardless of the stage of your project, Alfa Cytology is capable of providing comprehensive support and services. If you are interested in our services for bladder cancer small molecule drug development or have any inquiries, please do not hesitate to contact us. We will be delighted to assist you.
Reference
- Stecca, C., Abdeljalil, O., & Sridhar, S. S. Metastatic Urothelial Cancer: a rapidly changing treatment landscape. Therapeutic advances in medical oncology, 2021, 13, 17588359211047352.
For research use only. Not intended for any clinical use.
Related Services
